Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 10.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 320,625 shares of the medical research company’s stock after acquiring an additional 31,420 shares during the period. Dimensional Fund Advisors LP owned 0.63% of Charles River Laboratories International worth $69,871,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in CRL. Concord Wealth Partners acquired a new stake in Charles River Laboratories International in the fourth quarter valued at $33,000. Huntington National Bank raised its holdings in Charles River Laboratories International by 53.7% in the third quarter. Huntington National Bank now owns 189 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 66 shares in the last quarter. Allworth Financial LP raised its holdings in Charles River Laboratories International by 60.0% in the fourth quarter. Allworth Financial LP now owns 168 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 63 shares in the last quarter. Quent Capital LLC increased its stake in Charles River Laboratories International by 28.6% during the third quarter. Quent Capital LLC now owns 198 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 44 shares during the last quarter. Finally, Gradient Investments LLC increased its stake in Charles River Laboratories International by 6,200.0% during the fourth quarter. Gradient Investments LLC now owns 189 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 186 shares during the last quarter. 97.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CRL has been the subject of several recent research reports. TheStreet lowered shares of Charles River Laboratories International from a “b-” rating to a “c” rating in a research note on Thursday, May 11th. Wells Fargo & Company lowered their target price on shares of Charles River Laboratories International from $290.00 to $280.00 in a research note on Friday, May 12th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Charles River Laboratories International from $260.00 to $250.00 in a research note on Friday, May 12th. Jefferies Financial Group lowered their target price on shares of Charles River Laboratories International from $233.00 to $203.00 and set a “hold” rating for the company in a research note on Tuesday, March 28th. Finally, Morgan Stanley lowered their target price on shares of Charles River Laboratories International from $241.00 to $230.00 and set an “equal weight” rating for the company in a research note on Thursday, February 23rd. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International has an average rating of “Moderate Buy” and an average price target of $260.73.

Charles River Laboratories International Stock Down 2.3 %

Charles River Laboratories International stock opened at $194.89 on Friday. The company has a 50-day simple moving average of $195.96 and a 200-day simple moving average of $218.21. The firm has a market capitalization of $9.97 billion, a P/E ratio of 20.15, a P/E/G ratio of 1.41 and a beta of 1.34. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.21 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a one year low of $181.22 and a one year high of $262.00.

Charles River Laboratories International (NYSE:CRL – Get Rating) last announced its earnings results on Wednesday, February 22nd. The medical research company reported $2.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.75 by $0.23. The firm had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.04 billion. Charles River Laboratories International had a net margin of 12.13% and a return on equity of 20.12%. Charles River Laboratories International’s revenue was up 21.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.49 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 10.28 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 345 shares of the stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $190.39, for a total value of $65,684.55. Following the completion of the transaction, the executive vice president now owns 24,026 shares in the company, valued at approximately $4,574,310.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Profile

(Get Rating)

Charles River Laboratories International, Inc is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.